Caplin Point Laboratories Limited has announced significant changes in its leadership team. Dr. Sridhar Ganesan has been re-appointed as the Managing Director for a two-year term, effective August 25, 2026. Concurrently, Mr. D. Muralidharan has been appointed as a Whole-Time Director, also for two years from August 12, 2026, continuing his role as Chief Financial Officer.
Board Leadership Enhancements at Caplin Point
Caplin Point Laboratories Limited has formalized key leadership positions, aiming to ensure continuity and strategic direction. The company’s Board of Directors, following recommendations from the Nomination and Remuneration Committee, has approved significant appointments. These changes underscore the company’s commitment to maintaining strong governance and operational leadership.
Key Leadership Appointments
In a strategic move to ensure stable leadership, Dr. Sridhar Ganesan has been re-appointed as the Managing Director. His term is extended for a further period of two (2) years, commencing August 25, 2026, and concluding on August 24, 2028. This re-appointment is subject to shareholder approval at the upcoming Annual General Meeting (AGM).
Furthermore, Mr. D. Muralidharan has been appointed as the Whole-Time Director of the Company. This appointment is effective from August 12, 2026, and will span a period of two years, concluding on August 11, 2028. Mr. Muralidharan will continue to hold his position as the Chief Financial Officer alongside his new role as Whole-Time Director, integrating financial oversight with broader operational responsibilities.
Director Profiles and Compliance
Detailed information regarding the appointments, including brief profiles and disclosures of relationships, has been provided in Annexure-A. Both Dr. Sridhar Ganesan and Mr. D. Muralidharan have confirmed that they are not debarred from holding the office of director by any SEBI order or other such authority, ensuring compliance with all regulatory requirements.
Source: BSE
